ALTRUA 2 (Models S701, S702, S722) ESSENTIO (Models L100, L101, L121) PROPONENT (Models L200, L201, L221) ACCOLADE (
Boston Scientific Corp · Decision date Dec 19, 2025
What did the FDA approve?
FDA records N970003/S304 as a supplement to PMA null, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Dec 19, 2025.
FDA approval order statement
approval for the Software Maintenance Release 6 (SMR6) package of software updates for the ACCOLADE family of pacemakers and CRT-Ps
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Dec 19, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- N970003/S304
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific Corp
- Product code
- LWP
- Decision code
- APPR
- Decision date
- Dec 19, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implantable pulse generator, pacemaker (non-CRT).
- Applicant
- Boston Scientific Corp
- Product code
- LWP
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
N970003/S304 received
Application receipt date recorded by FDA.
N970003/S304 · FDA decision
Real-Time Process
Related devices and submissions
Explore the linked device profile
Other records with product code LWP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Oct 29, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 23, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 5, 2026 | FDA | |
| Boston Scientific Corp | PMA supplement | Oct 3, 2026 | FDA | |
| Boston Scientific | PMA supplement | Oct 3, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 4100 Hamline Ave. N, St Paul, MN, 55112
Sources and methodology
- Original FDA record: N970003/S304
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
